Today’s Budget and Growth Review contain promising developments for the pharmaceutical industry in the UK and show a real response to the challenges the industry faces. The combination of these measures should see the acceleration of the resurgence of the UK as a global destination site for clinical trials.
Announcements made today to strip bureaucracy around clinical trials, incentivising the NHS to improve access to trials and to review the NHS approach to the adoption of new medicines are a promising step forward for patient care.
The measures set out today reflect the remarkable success of the Office for Life Sciences and demonstrate the opportunities that can be realised when Government, Industry and Academia work in collaboration.
“Industry warmly welcomes measures in the Budget to cut red tape and improve the process for clinical trials, a significant step towards faster patient access to new medicines whilst also making the UK a more attractive place to do business. We look forward to working with the NHS Chief Executive on the report on the adoption of new medicines in the NHS which would be a very promising step forward. This, together with the package of measures around skills, IP, tax credits and breaks and the continuation of translational research partnerships, shows that Britain is a strong competitor and place to do business for our industry. The measures set out today reflect the success of the Office for Life Sciences and demonstrate the opportunities that can be realised when Government, Industry and Academia work in collaboration”.